News

Jail diversion programs offer vital support for individuals with mental health and substance use disorders, promoting recovery and reducing recidivism.

Let's investigate the complexities of diagnosing and treating ADHD in older adults, highlighting its prevalence, comorbidities, and treatment challenges.

This article is sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc., for which Dr. Ann Childress is a paid consultant.

Tonmya, a groundbreaking fibromyalgia treatment, is now available in the US, offering hope for millions suffering from chronic pain.

Misinformation about ADHD impacts treatment and self-perception. This Special Report clarifies misconceptions, promotes understanding, and supports informed care for individuals with ADHD.

AI can transform the tedious task of writing progress notes for psychiatrists, offering both efficiency and challenges in clinical practice.

Chatbots risk validating suicidal thoughts, highlighting the urgent need for ethical programming to prioritize user safety and human connection.

Explore the emerging field of spiritual psychiatry, addressing the intersection of mental health, ethics, and personal meaning in patient care.

Silo Pharma partners with Allucent to advance SPC-15, a novel treatment for PTSD, aiming for FDA approval and addressing unmet patient needs.

Learn more about the prevalence and implications of psychotropic polypharmacy in treatment-resistant schizophrenia.

Recent studies suggest lithium may effectively prevent cognitive decline and Alzheimer disease, challenging the dominance of lecanemab in early dementia treatment.

FDA expands Deep TMS therapy for adolescents with major depressive disorder, offering a noninvasive treatment option for underserved youth.

Explore the transformative potential of futures thinking in mental health, offering innovative frameworks to navigate uncertainty and enhance agency.

Explore the evolving role of lamotrigine in treating bipolar depression, highlighting its benefits, risks, and recent clinical guidelines.

New analysis reveals that negative symptoms and stimulant use may predict positive responses to Cobenfy in schizophrenia treatment.

Two promising psychiatrists have tragically passed away.

Iclepertin shows no significant cognitive improvement in schizophrenia patients despite good tolerability, highlighting challenges in treating cognitive impairment.

EXCLUSIVE: Check out this recap on the approval of lumateperone (Caplyta) for major depressive disorder.

Alixorexton shows promising results in improving wakefulness and reducing daytime sleepiness in patients with narcolepsy type 2.

"Without a father to guide me north, your poems were a compass pointing toward a world where doctors can be poets..."

FDA committee discusses potential and risks of AI-enabled digital mental health devices.

A recent study links lower income to higher dementia risk factors, highlighting the need for targeted interventions in vulnerable populations.

Explore how placebo effects vary across psychiatric disorders, revealing significant symptom improvements, especially in major depressive disorder and generalized anxiety disorder.

New phase 4 data reveals Austedo significantly reduces involuntary movements and enhances quality of life for adults with tardive dyskinesia.

Caplyta, now FDA-approved as an adjunctive therapy for major depressive disorder, offers rapid relief and a favorable safety profile for patients. Learn more from Suresh Durgam, MD, the primary investigator.

Explore the evolving understanding of haloperidol's risks and the shift towards safer alternatives in delirium management and psychiatric care.

Veterans face significant PTSD challenges, with tailored treatments and ongoing research essential for improving their mental health outcomes.

Neurocrine's NBI-1070770 fails to meet primary endpoint in phase 2 trial for major depressive disorder, prompting further analysis of results.

Dive into poetic reflections on life and aging.